3 Surprising New Health Benefits of Ozempic and Wegovy

In recent years, the medical world has been captivated by the rise of semaglutide-based drugs like Ozempic and Wegovy. Originally developed as GLP-1 receptor agonists to manage type 2 diabetes and promote weight loss, these medications have quickly become global bestsellers. 3 Surprising New Health Benefits of Ozempic and Wegovy

However, a wave of research published in 2026 reveals a much broader picture: semaglutide’s therapeutic reach extends into mental health, anti-aging, and respiratory care. At the same time, advanced artificial intelligence (AI) models analyzing real-world patient data have uncovered previously underreported side effects.

1. Mental Health Benefits: Reducing Bipolar Psychiatric Hospitalizations

Semaglutide is showing unexpected promise in psychiatry. A large-scale observational study led by Professor Mark Taylor from the School of Medicine and Dentistry at Griffith University, alongside an international research team, evaluated 15 years of national registry data from Sweden (2009–2024).

The study, published in Acta Psychiatrica Scandinavica, tracked nearly 15,000 individuals diagnosed with bipolar disorder who were prescribed GLP-1 receptor agonists.

• Lower Risk of Psychiatric Hospitalization: Patients with bipolar disorder taking semaglutide experienced a 21% lower risk of psychiatric hospitalization compared to periods when they were not taking GLP-1 medications.
• Drug Specificity: This mental health benefit was unique to semaglutide. Other GLP-1 medications, such as liraglutide and dulaglutide, did not show a statistically significant reduction in psychiatric hospitalizations.
• Biological Mechanism: Researchers hypothesize that semaglutide reduces neuroinflammation and cellular stress in the brain, which may help stabilize mood and lower relapse rates.

2. Anti-Aging Potential and Lifespan Extension

Beyond brain health, semaglutide may also influence the biological processes of aging. A study led by Danica Chen, Ph.D. and Yufan Feng, Ph.D. at the University of California, Berkeley (UC Berkeley)—in collaboration with the National Institute on Aging (NIA) and the University of Copenhagen—investigated the drug’s impact on aging models.

Published in Nature (September 2026) under the title “Late-life semaglutide treatment slows ageing and extends lifespan in female mice”, the study tested healthy, aged female mice (20 months old, roughly equivalent to a 60-year-old human).

• Extended Lifespan: Aged mice treated with semaglutide saw a 12% increase in median lifespan (living approximately 92 to 100 days longer) compared to the control group.
• Cognitive and Physical Enhancements: The treated mice demonstrated improvements in muscle strength, spatial memory, exploratory behavior, and glycemic control.
• Reversing Hallmarks of Aging: At the molecular level, semaglutide suppressed chronic inflammation, enhanced insulin sensitivity, and stimulated the regenerative capacity of brain and bone marrow stem cells.
• Distinct Metabolic Pathway: Unlike calorie restriction (a 24% reduction diet, long considered the gold standard in anti-aging research), semaglutide achieved these effects without lowering the animals’ metabolic rate, suggesting an independent biological mechanism.

3. Respiratory Protection: Curbing Asthma Attacks and COPD Flare-ups

A third major finding highlights semaglutide’s benefits for lung health. Research from Imperial College London, led by Professor Chloe Bloom and presented by Dr. Bohee Lee at the European Respiratory Society (ERS) Congress in Barcelona (September 2026), analyzed real-world electronic health records from the UK.

The team compared respiratory outcomes between patients with asthma or Chronic Obstructive Pulmonary Disease (COPD) who were taking GLP-1 receptor agonists versus those on other diabetes medications.

• 39% Reduction in Severe Asthma Attacks: Patients taking semaglutide experienced nearly 40% fewer severe asthma attacks.
• 20% Decrease in COPD Flare-ups: Semaglutide use was also associated with a 20% drop in COPD exacerbations.
• Anti-Inflammatory Action: The drug’s systemic anti-inflammatory properties appear to alleviate airway inflammation, offering dual metabolic and respiratory protection.

4. Side Effect Profile: From Common GI Issues to AI-Discovered Symptoms

While the therapeutic potential of Ozempic and Wegovy is expanding, understanding their full side effect profile remains vital. A computational social listening study led by Neil Sehgal, Sharath Chandra Guntuku, and Lyle Ungar at Penn Engineering (University of Pennsylvania) leveraged AI to examine real-world patient reports.

Published in Nature Health (April 2026), the research used Large Language Models (LLMs) to scan 410,198 Reddit posts from 67,008 unique users discussing GLP-1 medications between May 2019 and June 2025.

Most Commonly Reported Side Effects:

• Gastrointestinal (GI) Issues: Nausea (36.9%), vomiting (16.3%), constipation (15.3%), and diarrhea (12.6%).
• Fatigue: General tiredness or fatigue was reported by 16.7% of users experiencing side effects.

Newly Identified Symptoms (AI Pharmacovigilance Findings):

By mapping informal online discussions to standard medical terminology (MedDRA), the AI uncovered two previously underreported symptom clusters:

1. Menstrual Irregularities: Approximately 4% of female users reported disruptions to their menstrual cycles.
2. Body Temperature Dysregulation: A notable number of users reported unusual sensations of extreme cold (chills) or sudden heat flashes (hot flashes).

Researcher Note: The Penn Engineering team emphasized that these social media findings serve as early pharmacovigilance signals rather than definitive proof of causality, highlighting areas that warrant further investigation in formal clinical trials.

Conclusion

3 Surprising New Health Benefits of Ozempic and Wegovy. Ozempic and Wegovy (semaglutide) are rapidly evolving past their original roles as diabetes and weight management tools. Emerging evidence points to meaningful systemic benefits—ranging from reduced bipolar hospitalizations and asthma flare-ups to enhanced longevity markers. At the same time, ongoing real-world monitoring via AI underscores the importance of consulting healthcare providers to manage both common GI side effects and emerging body responses.